[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"functional-neurological-symptom-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:functional-neurological-symptom-disorder":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100627683","cognitive-disengagement-syndrome-in-functional-neurological-symptom-disorder-100627683",false,"NCT07451821","Cognitive Disengagement Syndrome in Functional Neurological Symptom Disorder","Symptoms of Sluggish Cognitive Tempo\u002FCognitive Disengagement Syndrome in Functional Neurological Symptom Disorder\u002FConversion Disorder: A Cross-Sectional Case-Control Study","* Inclusion Criteria for the Functional Neurological Symptom Disorder (FNSD) Group:\n\n  1. Meeting the diagnostic criteria for FNSD\u002FCD according to DSM-5-TR at the time of admission\n  2. Being between 18-65 years of age\n  3. Absence of additional psychiatric disorders\n  4. Absence of alcohol\u002Fsubstance use disorder\n  5. Absence of neurological disorders affecting cognition\n  6. Being in remission with FNSD\u002FCD\n  7. Completing sociodemographic data fully\n  8. Willingness to complete the forms and scales.\n  9. Willingness to participate in the study\n* Exclusion Criteria for the FNSD Group:\n\n  1. Being under 18 or over 65 years of age\n  2. Not meeting the diagnostic criteria for FNSD\u002FCD according to DSM-5-TR\n  3. Active alcohol\u002Fsubstance use\n  4. Having neurological diseases affecting cognitive functions (such as Alzheimer's disease, delirium, Parkinson's disease)\n  5. Not being willing to participate in the study\n  6. Incomplete sociodemographic data\n  7. Not being willing to complete forms and scales.\n* Inclusion Criteria for the Healthy Control (HC) Group\n\n  1. Being between 18-65 years of age\n  2. Not having any psychiatric disorder\n  3. Not having an alcohol\u002Fsubstance use disorder\n  4. Not having a neurological disorder affecting cognition\n  5. Completing sociodemographic data in full\n  6. Being willing to complete the forms and scales.\n  7. Being willing to participate in the study\n* Exclusion Criteria for the HC Group:\n\n  1. Being under 18 or over 65 years of age\n  2. Having a psychiatric disorder\n  3. Active alcohol\u002Fsubstance use\n  4. Having neurological diseases affecting cognitive functions (such as Alzheimer's disease, delirium, Parkinson's disease)\n  5. Not being willing to participate in the study\n  6. Incomplete sociodemographic data\n  7. Not being willing to complete forms and scales.",true,"ALL","18 Years","65 Years",{"count":21,"type":22},100,"ESTIMATED","OBSERVATIONAL","This cross-sectional observational case-control study aims to investigate symptoms of sluggish cognitive tempo (SCT), also known as cognitive disengagement syndrome (CDS), in adults diagnosed with Functional Neurological Symptom Disorder\u002FConversion Disorder (FNSD\u002FCD). The study compares SCT\u002FCDS symptoms between patients with FNSD\u002FCD and healthy controls and evaluates their relationship with clinical variables. It is hypothesized that individuals diagnosed with FNSD\u002FCD will exhibit higher levels of SCT\u002FCDS symptoms compared to healthy controls.",[26],"Functional Neurological Symptom Disorder",[28,29,30,26,31,32,33],"Sluggish Cognitive Tempo","Cognitive Disengagement Syndrome","Conversion Disorder","Dissociation","Attention","Daydreaming","NOT_YET_RECRUITING","2026-06-24",{"date":37,"type":38},"2026-06-29","ACTUAL",{"date":40,"type":22},"2026-07-01",{"date":42,"type":22},"2026-12-24",{"name":44,"class":45},"Elazığ Mental Health and Diseases Hospital","OTHER_GOV",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":46},"100597502","early-phase-1-accelerated-tms-for-seizure-type-functional-neurologic-disorders-100597502","NCT07059325","Accelerated TMS for Seizure-Type Functional Neurologic Disorders","Accelerated, Left Prefrontal Transcranial Magnetic Stimulation for Functional Seizures; An Open-Label Exploration of Feasibility, Tolerability, and Preliminary Efficacy","FND-seiz","Inclusion Criteria:\n\n1. \\>18 years old and \\\u003C65 years old\n2. English Speaking, can read and write, and able to provide informed consent\n3. Diagnosis of \"documented\" Functional Seizures as made by an MUSC epileptologist or neurologist using the ILAE recommendations: \"by clinician experienced in diagnosis of seizure disorders (on video or in person), showing semiology of typical of FND-seiz, while on EEG plus no epileptiform activity on routine or ambulatory ictal EEG during a typical ictus\u002Fevent in which the semiology would make ictal epileptiform EEG activity expected during equivalent epileptic seizures\"2\n4. In addition to meeting ILAE minimum requirements for FND-seiz diagnosis, must have previously undergone and documented in the electronic medical record a minimum of 24-hours of otherwise normal video EEG without interictal epileptiform findings\n5. Duration of symptoms \\>3 months and continuing to experience NES at least monthly\n6. Not currently undergoing any psychotherapeutic intervention, agree to forgo any psychotherapeutic intervention during the study, and if previously completed any psychotherapeutic intervention continue to experience monthly non-epileptic seizures\n7. If on psychotropic medications may choose to continue during the duration of the study at current doses, but consent to not modifying medication doses or switching to alternative psychotropic regimens during the trial\n8. In good general health, as ascertained by medical history\n9. Females of reproductive age (ages 18 to 50) must have a negative urine pregnancy test, performed onsite, and documented in the study record within 72 hours prior to the first TMS session\n\nExclusion Criteria:\n\n1. History of clinical concern for concomitant epileptic seizures or epilepsy\n2. History of ongoing psychosis, mania, active alcohol or substance use disorder as screened by the PSQ, YMRS, AUDIT, and DAST-10\n3. History of positive screening urine test for drugs of abuse within the last year: cocaine, amphetamines, barbiturates, opiates\n4. Active suicidal intent or a score \\>2 on question 3 of the HAM-D\n5. Use of medications known to lower the seizure threshold at doses that may increase this risk in the setting of rTMS-iTBS (i.e. buproprion at \\>300 mg, combinations of tricyclic antidepressants, antipsychotics… as determined by investigators)\n6. History of central nervous system surgeries or clinically relevant structural brain lesions\n7. Significant or unstable cardiac, metabolic, oncologic, psychiatric, developmental, or neurologic condition(s) or treatments that may impact safe participation in the study as determined by the study investigators (e.g. poorly-controlled heart failure, current or past cardiac arrhythmia, sustained systolic blood pressure \\>180, labile diabetes, significant electrolyte abnormality, brain cancer, cognitive impairment, neurodevelopmental disorders, autism spectrum disorder, mania, schizophrenia spectrum or other psychotic disorder, movement disorders, multiple sclerosis, moderate to severe brain injury)\n8. Participation in any clinical trial with an investigational drug or device within the past month or concurrent to study participation\n9. History of TMS exposure\n10. TMS contraindications (e.g., ferromagnetic implants, cochlear implants, conditions or treat-ments that lower seizure threshold - as determined by study investigators).\n11. Current pregnancy or desire to become pregnant during study duration without contraceptive plan\n12. Are a prisoner or in police custody at the time of eligibility screening",{"count":56,"type":22},30,"INTERVENTIONAL",[59],"EARLY_PHASE1","The purpose of this project is to assess the feasibility, tolerability, and preliminary efficacy of using an accelerated, intermittent theta burst stimulation (a-iTBS-rTMS) protocol targeting the left dorsolateral prefrontal cortex (l-dlPFC) for Psychogenic Non-Epileptic Seizures (PNES) or Seizure-Type Functional Neurologic Disorder (FND-seiz) in an open-label fashion. Following screening, consent, and enrollment, participants will receive 6-to-10 iTBS-rTMS sessions per day (i.e., theta burst; 600 pulses per session; 6000 pulses per day) over a 3-to-5 treatment days with a target of 30 total sessions (18,000 total pulses). TMS will be targeted to Beam F3 for comparison to the bulk of the literature and to most mimic replicable and clinical use. This proposed iTBS-rTMS protocol was chosen given its previously shown safety, tolerability, and effectiveness in other conditions, but also as it has the potential to shorten treatment to only 3 days, which investigators theorize will be more feasible for patients with FND-seiz.\n\nFeasibility will be measured as the percentage of participants who receive at least 20 treatment sessions within the 3-to-5-day window. Other than self-assessments used in the safety screening process or to monitor TMS benefits and risks, secondary subjective measures will assess previously investigated FND-seiz-specific outcomes, which will be obtained prior to intervention and 4-weeks post-intervention. In addition to monthly seizure frequency, this will include validated measures regarding stigma, health-related QOL, depression, PTSD, somatic symptoms, psychosocial functioning, psychological distress, and clinical and participant impression of improvement and satisfaction. Sub-analysis will further divide participants with mild to no depression and\u002For PTSD versus moderate to severe depression and\u002For PTSD to further assess how the TMS effects known to effect other highly comorbid disorders with FND-seiz, may indirectly affect FND-seiz outcomes.",[26,62],"Functional Seizures",[64,65,62,66],"Mental Health","Psychiatry","Transcranial Magnetic Stimulation","RECRUITING","2025-09-16",{"date":70,"type":38},"2025-09-22",{"date":72,"type":38},"2025-09-02",{"date":74,"type":22},"2027-07-01",{"name":76,"class":77},"Medical University of South Carolina","OTHER"]